UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): ~~October~~January 186, ~~2018~~2020

E-QURE CORP.

(Exact Name of Registrant as Specified in its Charter)

Commission File No.: 000-54862

Delaware		47-1691054
(State of Incorporation)		(I.R.S. Employer Identification No.)
(State or other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)
20 West 64th Street, Suite 39G, New York, NY		10023
(Address of Principal Executive Offices)		(Zip Code)

20 West 64th Street, Suite 39G, New York, NY		10023
(Address of Principal Executive Offices)		(ZIP Code)

Registrant’s Telephone Number, including area code: + (972) 54-422-7777

Registrant's Telephone Number, including area code: (972) 8-916-7333

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(g) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.00001		EQUR		OTCQB

Item 8.01 Other Events.

E-Qure Corp., a Delaware corporation, OTCQB: EQUR (the “Company”), ~~reported~~a ~~today~~medical ~~that~~device itCompany, ~~has~~reported ~~successfully~~today ~~completed~~the ~~its 2018 funding~~following ~~program~~material inupdates ~~the~~regarding ~~total~~Bioelectrical ~~amount~~Signal ofTherapy ~~$1.231~~device ~~Million~~ (~~the~~ “~~2018~~BST ~~Funding Program”~~Device). ~~The~~developed ~~2018~~for ~~Funding~~the ~~Program~~treatment ~~included~~of ~~three~~wounds ~~stages~~via electrical stimulation, which ~~included:~~is ~~(1)~~believed ~~the~~to ~~successfully~~result ~~closing~~in ofaccelerated ~~its~~wound ~~Subscription~~healing ~~Rights~~by ~~Offering~~imitating ~~pursuant~~the tonatural aelectrical ~~registration statement~~current onthat ~~Form~~occurs ~~S-1~~in ~~(the~~injured ~~“Registration~~skin ~~Statement”);~~on ~~(2)~~ the ~~completion~~human ofbody. ~~the~~Our ~~Company’s~~BST ~~private~~Device ~~Unit~~stimulates ~~Offering~~renewed ~~pursuant to~~blood ~~Regulation~~flow ~~S (the “Reg S Unit Offering”;~~ and ~~(3)~~oxygen ~~the~~in ~~conversion~~order ~~of debt~~ to ~~equity~~induce bylocal cell ~~its~~regeneration ~~management~~and ~~team,~~therefore ~~all~~promote ~~as discussed~~wound ~~more fully below~~healing.

In1. ~~June~~The ~~2018,~~Company ~~the~~has ~~Company~~been ~~received~~granted ~~net~~with ~~proceeds~~the Helsinki committee approval of ~~$532~~Clalit Health Services Organization,~~147~~ ~~from~~Israel’s largest HMO, and the ~~Subscription~~Israeli ~~Rights~~Ministry ~~Offering~~of ~~pursuant~~Health (MOH) to launch a Randomized Control Study (RCT) on 60-100 patients in order to assess the ~~Registration~~efficacy ~~Statement~~of the BST Device on diabetic foot patients. The study will be performed in 3-5 sites including leading clinics and ~~that~~hospitals ~~was~~in ~~declared~~Israel. ~~effective~~The ~~under~~Company intends to enroll the ~~Securities~~first ~~Act~~patients ofto ~~1933,~~the asstudy ~~amended~~during (the ~~“Act”)~~next by2-3 weeks and expects the ~~SEC~~trial to onbe ~~May~~conducted ~~10,~~for ~~2018~~12-18 months until completion.

~~Following~~2. ~~the~~The ~~second quarter ended June 30, 2018, the~~ Company, ~~pursuant~~has toconcluded ~~its~~a ~~Reg S Unit Offering~~35-wound, ~~raised~~one anarm ~~additional~~clinical ~~$423~~pilot,~~400~~ ~~from~~treating ~~the private~~recalcitrant ~~sale~~wounds ofin a ~~total~~leading ofwound ~~4,234,000~~clinic ~~Units~~in atTel ~~$0.10 per Unit~~Aviv Israel, ~~each~~with ~~consisting~~78% of: ~~(i)~~the ~~one~~treated ~~share~~wounds ofcompletely ~~Common~~healed ~~Stock;~~within ~~(ii)~~20 ~~one~~weeks ~~Class A~~(Avg. ~~Warrant~~wound ~~exercisable~~duration ~~for~~at athe ~~period~~base ofwas 248 months) toand ~~purchase~~an additional ½16% ~~share~~ of ~~Common Stock at~~ the ~~equivalent~~treated ofwounds ~~$0.50~~reaching ~~per~~wound ~~share; and~~area ~~(iii)~~reduction ~~one Callable Class B Warrant exercisable for a period~~ of 36greater ~~months~~than to75%. ~~purchase~~Only ½6% ~~share~~ of ~~Common Stock at~~ the ~~equivalent~~ ofpatients ~~$1.25~~had ~~per~~no ~~share. The Reg S Unit Offering was made in an “offshore transaction” to 18 accredited, all~~substantial ofpositive ~~whom~~clinical ~~were non “U~~effect.~~S. Persons” as defined in Rule 902(h) promulgated by the SEC under the Act.~~

In3. ~~addition,~~The ~~after the quarter ended June 30, 2018, the~~ Company’s ~~executive~~recently ~~officers~~filed ~~and chairman converted debt in the aggregate amount of $275,303 into units consisting of~~ a ~~total~~provisional ~~of:~~patent ~~(i)~~with ~~2,753,030~~United ~~restricted~~States ~~shares,~~Patent ~~1,376,515 Class A Warrants~~ and ~~Class B~~Trademark ~~Warrants,~~Office ~~having~~for the ~~same~~purpose ~~terms~~of asprotecting the ~~Class A and Class B Warrants set forth in the Reg S Unit Offering, and 2,750,000 Class~~ Cmain ~~Warrants~~features ~~exercisable to purchase one share~~ of ~~Common~~our ~~Stock~~proprietary atunique aelectrical ~~price~~healing ofsignal ~~$1.00~~BST ~~per Share~~Device.

~~The~~4. The Company’s ~~intends~~distributor toin ~~use~~Colombia, ~~the~~TekMedica ~~total~~SAS, ~~equity~~has ~~capital~~successfully ~~raised~~concluded ~~under~~a ~~its~~clinical ~~Registration~~pilot ~~Statement~~study ~~and~~at ~~Reg~~the SHospital de ~~Unit~~la ~~Offering~~Samaritana ~~for~~in ~~general~~Bogota, ~~corporate purposes~~Colombia. Starting in January 2020, ~~including~~Colsanitas, ~~working~~a ~~capital~~leading ~~and~~Colombian ~~capital~~HMO/Health ~~expenditures~~insurance inprovider and ~~furtherance~~operator of ~~development~~comprehensive healthcare services in Colombia and ~~commercialization~~a member of ~~its~~the ~~BST~~Sanitas ~~Device~~group worldwide, will commence a ~~new~~clinical pilot ~~and~~study ~~novel~~which ~~electrotherapy~~is ~~for~~expected ~~the~~to ~~non-invasive~~be ~~treatment~~concluded by the end of ~~hard-to-heal~~the ~~chronic~~first ~~wounds~~half of 2020. ~~The~~If ~~BST~~positive ~~Device~~results ~~has~~are ~~received~~achieved, similar to those achieved in the ~~Conformité~~Tel ~~Européenne~~Aviv ~~(European~~clinical ~~Conformity~~trials, ~~-“CE”)~~the ~~mark~~Company ~~and~~believes ~~was~~that ~~approved~~it will contribute to bethe ~~sold~~penetration inof the BST EUdevice ~~market~~treatment with Colsanitas health services in Colombia.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

E-QURE CORP. By: /s/: Ron Weissberg Name: Ron Weissberg Title: Chairman

E-QURE CORP.

	/s/: Ohad Goren
Name:	Ohad Goren
Title:	Chief Executive Officer
Dated:	January 21, 2020

Date: October 18, 2018

Filing Compare · E-Qure Corp.